Risk of Injection-Site Abscess among Infants Receiving a Preservative-Free, Two-Dose Vial Formulation of Pneumococcal Conjugate Vaccine in Kenya

There is a theoretical risk of adverse events following immunization with a preservative-free, 2-dose vial formulation of 10-valent-pneumococcal conjugate vaccine (PCV10). We set out to measure this risk. Four population-based surveillance sites in Kenya (total annual birth cohort of 11,500 infants)...

Descripción completa

Detalles Bibliográficos
Autores principales: Burton, Deron C., Bigogo, Godfrey M., Audi, Allan O., Williamson, John, Munge, Kenneth, Wafula, Jackline, Ouma, Dominic, Khagayi, Sammy, Mugoya, Isaac, Mburu, James, Muema, Shadrack, Bauni, Evasius, Bwanaali, Tahreni, Feikin, Daniel R., Ochieng, Peter M., Mogeni, Ondari D., Otieno, George A., Olack, Beatrice, Kamau, Tatu, Van Dyke, Melissa K., Chen, Robert, Farrington, Paddy, Montgomery, Joel M., Breiman, Robert F., Scott, J. Anthony G., Laserson, Kayla F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625023/
https://www.ncbi.nlm.nih.gov/pubmed/26509274
http://dx.doi.org/10.1371/journal.pone.0141896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625023/
https://www.ncbi.nlm.nih.gov/pubmed/26509274
http://dx.doi.org/10.1371/journal.pone.0141896

Ejemplares similares